Amgen, Inc. (NASDAQ:AMGN) Shares Acquired by Institute for Wealth Management LLC.

Share on StockTwits

Institute for Wealth Management LLC. lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,804 shares of the medical research company’s stock after acquiring an additional 1,422 shares during the quarter. Amgen accounts for approximately 0.7% of Institute for Wealth Management LLC.’s portfolio, making the stock its 20th largest holding. Institute for Wealth Management LLC.’s holdings in Amgen were worth $3,281,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Bangor Savings Bank boosted its holdings in Amgen by 2.1% during the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock worth $510,000 after buying an additional 55 shares in the last quarter. Carroll Financial Associates Inc. boosted its holdings in Amgen by 0.8% during the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after buying an additional 58 shares in the last quarter. Lincoln Capital Corp boosted its holdings in Amgen by 0.3% during the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after buying an additional 58 shares in the last quarter. Slow Capital Inc. boosted its holdings in Amgen by 0.4% during the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after buying an additional 58 shares in the last quarter. Finally, CWM LLC boosted its holdings in Amgen by 1.8% during the second quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock worth $603,000 after buying an additional 59 shares in the last quarter. Institutional investors and hedge funds own 78.96% of the company’s stock.

Shares of NASDAQ AMGN traded up $4.71 on Friday, hitting $204.02. The company’s stock had a trading volume of 2,922,500 shares, compared to its average volume of 3,881,659. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $211.90. The company has a market capitalization of $119.53 billion, a price-to-earnings ratio of 14.17, a price-to-earnings-growth ratio of 2.34 and a beta of 1.19. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The stock has a 50 day moving average of $183.92 and a 200-day moving average of $182.82.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.58 by $0.39. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.83 earnings per share. Sell-side analysts expect that Amgen, Inc. will post 14.25 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be paid a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Wednesday, August 14th. Amgen’s payout ratio is 40.28%.

Several brokerages have issued reports on AMGN. BMO Capital Markets set a $230.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Wednesday, July 31st. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co upped their price target on shares of Amgen from $197.00 to $202.00 and gave the company a “market perform” rating in a report on Monday, August 12th. Morgan Stanley reduced their price target on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Finally, Evercore ISI reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Amgen currently has an average rating of “Buy” and a consensus price target of $212.72.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock worth $804,312 in the last three months. Insiders own 0.25% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: What is Elliott Wave theory?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.